30568-27-5

Usage

Uses

Used in Organic Synthesis:
2-methyl-2-(3-methylphenyl)propanenitrile serves as a reagent in organic synthesis, facilitating the creation of a variety of chemical compounds due to its unique structural features.
Used in Pharmaceutical Production:
In the pharmaceutical industry, 2-methyl-2-(3-methylphenyl)propanenitrile is utilized as an intermediate in the synthesis of various pharmaceuticals, contributing to the development of new medications.
Used in Pesticide Manufacturing:
2-methyl-2-(3-methylphenyl)propanenitrile also plays a role in the production of pesticides, where it acts as an intermediate to help create effective and targeted pest control agents.
Used in Dye Production:
2-methyl-2-(3-methylphenyl)propanenitrile is employed in the synthesis of dyes, where its chemical properties contribute to the creation of a range of colorants for different applications.
Safety Considerations:
Given its potential to irritate the skin, eyes, and respiratory system, 2-methyl-2-(3-methylphenyl)propanenitrile requires careful handling and adherence to safety precautions to minimize health risks during its use in various applications.

Upstream product

• 2947-60-6 3-methylbenzyl cyanide 
• 74-88-4 methyl iodide 
• 78-82-0 Isobutyronitrile 
• 352-70-5 m-Fluorotoluene 

Downstream Products

• 93351-25-8 2-methyl-2-m-tolylpropanoic acid 
• 32454-27-6 2-methyl-2-(m-tolyl)propan-1-ol 
• 19884-68-5 2,3-Dimethyl-3-(3-methyl-phenyl)-2-chlor-butan 
• 363186-16-7 α,α,3-trimethylbenzeneacetic acid ethyl ester 

Relevant academic research and scientific papers

Palladium-Catalyzed Distal m-C-H Functionalization of Arylacetic Acid Derivatives

Herein, we present m-C-H olefination on derivatives of phenylacetic acids by tethering with a simple nitrile-based template through palladium catalysis. Notably, the versatility of the method is evaluated with a wide range of phenylacetic acid derivatives for obtaining the meta-olefination products in fair to excellent yields with outstanding selectivities under mild conditions. Significantly, the present strategy is successfully exemplified for the synthesis of drugs/natural product analogues (naproxen, ibuprofen, paracetamol, and cholesterol).

Synthesis of indolines by copper-mediated intramolecular aromatic C-H amination

A Cu(OAc)2-mediated intramolecular aromatic C-H amination proceeds with the aid of a picolinamide-type bidentate coordination group to deliver the corresponding indolines in good yields. The reaction occurs smoothly even under noble-metal-free conditions, and in some cases the use of an MnO2 terminal oxidant renders the process catalytic in Cu. The mild oxidation aptitude of Cu(OAc)2 and/or MnO2 accommodates the formation of electron-rich thiophene-and indole-fused indoline analogues. The Cu-based system can provide an effective approach to various indolines of potent interest in pharmaceutical and medicinal chemistry.

PPARG MODULATORS FOR TREATMENT OF OSTEOPOROSIS

The invention provides methods of treatment of a progressive bone disease, such as osteoporosis, Paget's Disease, multiple myeloma, or hyperparathyroidism, comprising administration of an effective amount of a non-agonist PPARG modulator to a patient afflicted with the disease.

N-BENZYLINDOLE MODULATORS OF PPARG

The invention provides molecular entities that bind with high affinity to PPARG (PPARγ), and inhibit kinase-mediated (e.g., cdk5-mediated) phosphorylation of PPARG, but do not exert an agonistic effect on PPARG. Compounds of the invention can be used for treatment of conditions in patients wherein PPARG plays a role, such as diabetes, insulin resistance, impaired glucose tolerance, pre-diabetes, hyperglycemia, hyperinsulinemia, obesity, or inflammation. Side effects such as significant weight gain, edema, impairment of bone growth or formation, or cardiac hypertrophy, or any combination thereof, can be avoided in the mammal receiving the compound. Methods of preparation of the compounds, bioassay methods for evaluating compounds of the invention as non-agonistic PPARG binding compounds, and pharmaceutical compositions are also provided.

Process for preparing benzylnitriles

A process is described for preparing an aromatic compound substituted by a tertiary nitrile of Formula (1.0.0): comprising treating a substituted aromatic compound of Formula (2.0.0): with a secondary nitrile of Formula (3.0.0): in the presence of a base having a pKanumerical value in the range of from about 17 to about 30, provided that the difference in pKanumerical values between said base and the corresponding tertiary nitrile of Formula (3.0.0) is no more than about 6; in an aprotic solvent having a dielectric constant (∈) of less than about 20; and at a reaction temperature in the range of from about 0° C. to about 120° C.; whereby there is formed said tertiary-nitrile-substituted aromatic compound final product of Formula (1.0.0); wherein the constituent parts W1, W2, W3, W4, and W5; and the substituent moieties R1, R2, R3, R4, R5, R6, and R7in the compounds of Formulas (1.0.0), (2.0.0) and (3.0.0) are selected from known organic groups and radicals as further detailed in the instant specification.

The Stereochemistry of Organometallic Compounds. XXVII. Nucleophilic and Electrophilic Substitution Reactions of Conformationally Restricted Arenechromium Compounds

The regioselectivity of reaction of tricarbonyl(1,1-dimethylindane)chromium with selected electrophiles and nucleophiles has been shown to be influenced by the preferred conformation of the tricarbonylchromium group.Nucleophiles preferentially react at carbon atoms eclipsed by a chromium-carbonyl bond and electrophiles at carbon atoms in staggered positions.When similar reactions were attempted with some chelated arenechromium dicarbonyl phosphorus compounds only low yields of substitution products were obtained.